Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing

Osteoporosis International

Volumn 15, Issue 6, 2004, Pages 423-433

  Bauss, Frieder ^a   Russell, R Graham G ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bisphosphonate; Ibandronate; Intermittent; Osteoporosis; Preclinical

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DOG; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; IMMOBILIZATION; MONKEY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ANALYSIS; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 3042643207     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-004-1612-7     Document Type: Review

References (103)

1. Marcus R, Majumder S (2001) The nature of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, London, p 3
2. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, No. 843. WHO, Geneva
3. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
4. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850
5. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026
6. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S-17S
7. st century. Am J Med 103:20S-26S
8. National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 9:S1-S88
9. Ray NF, Chan JK, Thamer M, Melton LJ 3rd (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
10. Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, London, pp 631-649
11. Brown J, Kendler D, McClung M et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
12. Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milan) 12:1-12
13. Caro J, Huybrechts K, Ishak K, Naujoks C (2002) The impact of adherence to osteoporosis therapy on fracture rates in actual practice. Value Health 5:127
14. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886
15. Ralston SH, Thiebaud D, Herrmann Z et al (1997) Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 75:295-300
16. Herrmann Z, Schoeter KH (1999) The new bisphosphonate ibandronate in the treatment of tumor-induced hypercalcemia. Onkologie 22:208-211
17. Tripathy D, Budde M, Bergstrom B (2002) Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group). Ann Oncol 13[Suppl 5]:168 (Abstract)
18. Body JJ, Diel IJ, Lichinitser MR et al (2003) Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (MF4265 study group). Ann Oncol 14:1399-1405
19. Body JJ (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28[Suppl 11]:49-53
20. Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9:S66-S80
21. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
22. Mühlbauer RC, Bauss F, Schenk R et al (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
23. Bauss F, Mühlbauer RC (1994) BM 21.0955, monosodium salt monohydrate. Drugs Future 19:13-16
24. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S (1994) Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882
25. Fleisch H (ed) (1995) Bisphosphonates in bone disease: from the laboratory to the patient. Parthenon, New York
26. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
27. Green JR (2001) Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 28[Suppl 6]:4-10
28. Bauss F (1997) Ibandronate in malignant bone diseases and osteoporosis: preclinical results. Onkologie 20:204-208
29. Schimmer R, Bauss F (2003) Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25:19-34
30. Pecherstorfer M, Ludwig H, Schlosser K et al (1996) Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11:587-593
31. Neugebauer G, Köhler W, Akinkunmi L et al (2001) Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man. Proc Am Soc Clin Oncol 20:122a (Abstract)
32. Reid DM, Adami S, Recker RR, Bonvoisin B, Schimmer RC, Miller P (2003) Intermittent intravenous ibandronate injection: a novel dosing option in postmenopausal osteoporosis. Osteoporos Int 14[Suppl 7]:S57 (Abstract)
33. Miller P, Recker RR, Adami S, Bonvoisin B, Schimmer RC (2003) Rationale for intermittent intravenous ibandronate injections in postmenopausal osteoporosis. J Bone Miner Res 18[Suppl 2]:S263 (Abstract)
34. Adami S, Delmas P, Felsenberg D et al (2002) Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos Int 13[Suppl 1]:S14 (Abstract O36)
35. Stakkestad JA, Benevolenskaya LI, Stepan JJ et al (2003) Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62:969-975
36. World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva
37. Bonjour JP, Ammann P, Rizzoli R (1999) Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 9:379-393
38. Yamazaki I, Yamagucki H (1989) Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res 4:13-22
39. Jerome CP, Turner CH, Lees CJ (1997) Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265-270
40. Faugere M-C, Friedler RM, Fanti P, Malluche HH (1990) Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study emplying sequential biopsies. J Bone Miner Res 5:263-272
41. Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on involutional osteoporosis in women. European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London
42. United States Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. U.S. Food and Drug Administration, Rockville, MD
43. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192
44. Frost HM, Jee WSS (1992) On the rat model of human osteoporosis. Bone Miner 18:227-236
45. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
46. Fleisch H (2001) Basic biology of bisphosphonates. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, London, pp 449-467
47. Bauss F, Endele R, Besenfelder E, Hoelck J-P (2002) Ibandronate: Serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcif Tissue Int 70:289-290
48. Bauss F, Lalla S, Endele R, Hothorn LH (2002) The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29:2200-2208
49. Lin JH, Chen IW, Duggan DE (1992) Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478
50. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH (1993) A new bisphosphonate, BM 21.0955 prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8:1345-1355
51. Monier-Faugere MC, Geng Z, Paschalis EP et al (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
52. Fleisch H (1996) The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45C kinetics in the intact rat. Osteoporos Int 6:166-170
53. Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45-53
54. Daphtary M, Ruff C, Lee J, Shapiro J, Bauss F, Schultheis L (2001) Effect of ibandronate on bone quality under 50% and 100% weight-bearing conditions. J Bone Miner Res 16[Suppl 1]:S363 (Abstract)
55. Schultheis L, Ruff GB, Rastogi S et al (2000) Disuse bone loss in hindquarter suspended rats: partial weight-bearing, exercise and ibandronate treatment as countermeasures. J Gravit Physiol 7:P13-P14
56. Smith SY, Recker RR, Hannan, M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55
57. Glueer CC, Scholz-Ahrenz KE, Timm W et al (2002) The minipig is a good model for glucocorticoid-induced bone loss and shows efficacy of ibandronate treatment for this disorder. J Bone Miner Res 17[Suppl 1]:S371 (Abstract)
58. Müller R, Bauss F, Smith SY, Hannan MK (2001) Mechanostructure relationships in normal, ovariectomized and ibandronate treated aged macaques as assessed by microtomographic imaging and biomechanical testing. 47th annual meeting, Orthop Res Soc, San Francisco, p 0066
59. Bauss F, Wagner M, Hothorn LH (2002) The total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29:990-998
60. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F (1998) Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 8:97-103
61. Malluche HH, Shermann D, Meyer W, Ritz E, Norman AW, Massry SG (1982) Effects of long-term infusion of physiologic doses of 1-34 PTH on bone. Am J Physiol 242:F197-F201
62. Lundon K, Grynpas M (1993) The long-term effect of ovariectomy on the quality and quantity of cortical bone in the young cynomolgus monkey: a comparison of density fractionation and histomorphometric techniques. Bone 14:389-395
63. Rizzoli R, Caverzasio J, Bauss F, Bonjour JP (1992) Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone 13:321-325
64. Wallach S, Feinblatt JD, Carstens JH Jr, Avioli LV (1992) The bone "quality" problem. Calcif Tissue Int 51:169-172
65. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608
66. Burr DB (1993) Remodeling and the repair of fatigue damage. Calcif Tissue Int 53[Suppl 1]:S75-S81
67. Kinney JH, Ladd AJC (1998) The relationship between three-dimensional connectivity and the elastic properties of trabecular bone. J Bone Miner Res 13:839-845
68. Kurth AHA, Kim S-Z, Sedlmeyer I, Hovy L, Bauss, F (2000) Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br 82-B:126-130
69. Kurth AA, Kim S-Z, Sedlmeyer I, Bauss F, Shea M (2002) Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone 30:300-306
70. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283-8
71. Bauss F, Schenk RK, Hört S, Müller-Beckmann B, Sponer G(2003) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharm Tox Methods (in press)
72. Affentranger U, Bauss F, Qin L, Cordey J, McIff T, Rahn BA (1995) Mechanical properties of cancellous and cortical bone after long term ibandronate dosing in beagle dogs. Bone 17:604
73. Eberhardt C, Sayer J, Grüner E, Schwarz M, Bauss F, Kurth AA (2002) Ibandronate reduces the time of implant osseointergration in a rat model. Bone 30[Suppl]:40S (Abstract)
74. Gasser JA, Green JR (2001) Single intravenous administration of zoledronic acid exerts a long-term protective effect against cancellous and cortical bone loss in ovariectomized rats. J Bone Miner Res 16[Suppl 1]:SU414 (Abstract)
75. Ammann P, Rizzoli R, Caverzasio J, Shigematsu T, Slosman D, Bonjour JP (1993) Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. J Bone Miner Res 8:1491-1498
76. Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6:339-346
77. Rodan GA, Seedor JG, Balena R (1993) Preclinical pharmacology of alendronate. Osteoporos Int 3[Suppl 3]:S7-12
78. Kimmel DB (1991) Quantitative histological changes in the proximal tibial growth cartilage of aged female rats. Cells Mater [Suppl 1]:11-18
79. Russell RG (2002) Understanding intermittent therapy: potency and persistence. Osteoporos Int 13[Suppl 3]:S77
80. Leu C, Rodan GA, Reszka AA (2003) Relative binding affinities of bisphosphonates for human bone. J Bone Miner Res 18[Suppl 2]:S374 (Abstract)
81. Fournier P, Boissier S, Filleuer S, Gugliemmi J, Cabon M, Clézardin P (2002) Bisphsophonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544
82. Fleisch H (ed) (2000) Bisphosphonates in bone disease: from the laboratory to the patient. Academic Press, San Diego, CA
83. Nancollas GH, Tang R, Gulde S, Ebetino FH, Phipps RJ, Russell RGG (2002) Mineral binding affinities and zeta potential of bisphosphonates. J Bone Miner Res 17 [Suppl 1]:S368 (Abstract)
84. 2MDP). In: Association Corporative des Etudiants en Médicine de Lyon, Lyon, pp 16-19
85. Laurén L, Österman T, Kari T (1991) Pharmakokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections to rats. Pharmacol Toxicol 69:365-368
86. 14C-Clodronate in mice and rats. Pharmacol Toxicol 62:51-53
87. Lin JH, Duggan DE, Chen I-W, Ellsworth RL (1991) Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932
88. FDA (2002) Actonel (risedronate sodium) tablets. FDA: Center for Drug Evaluation and Research, Rockville, MD. http://www.fda.gov/cder/foi/nda/98/ 20835_Actonel.htm Cited 7 March 2004
89. FDA (2003) Zometa (zoledronic acid) injection. FDA: Center for Drug Evaluation and Research, Rockville, MD. http:// www.fda.gov/cder/foi/nda/2001/ 21-233_Zometa.htm Cited 7 March 2004
90. Reid IR, Brown JP, Burckhardt P (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
91. Cooper C, Bianchi G, Sørensen OH et al (2002) Importance of the total dose concept with bisphosphonates in postmenopausal osteoporosis: recent clinical evidence from ibandronate. Osteoporos Int 13[Suppl 3]:S34 (Abstract)
92. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 6:1871-1878
93. Delmas P, Recker R, Stakkestad JA et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study. Osteoporos Int 13[Suppl 1]:S15 (Abstract)
94. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. J Rheumatol (in press)
95. Stakkestad J, Nordby A, Skag A et al (2003) Three-monthly intravenous ibandronate injections: a novel treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis (in press)
96. Meunier PJ, Recker RR, Weinstein RS, Chesnut III CH, Bonvoisin B, Mahoney P (2003) Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis. (in press)
97. Cooper C, Delmas PD, Coutant K, Bonvoisin B, Recker RR (2003) Oral monthly ibandronate in postmenopausal osteoporosis: rationale and design of the MOBILE study. Osteoporos Int 14[Suppl 7]:S55 (Abstract P213)
98. Adami S, Recker RR, Reid DM et al (2003) Intermittent ibandronate injections in postmenopausal osteoporosis: rationale and design of the Dosing IntraVenous Administration (DIVA) study. Osteoporos Int 14[Suppl 7]:S56 (Abstract P217)
99. Ayd FJ Jr (1974) Single daily dose of antidepressants. JAMA 230:263-264
100. Coutts JA, Gibson NA, Paton JY (1992) Measuring compliance with inhaled medication in asthma. Arch Dis Child 67:332-333
101. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? a novel assessment technique. JAMA 261:3273-3277
102. Greenberg RN (1984) Overview of patient compliance with medication dosing: a literature review. Clin Ther 6:592-599
103. Venturini F, Nichol MB, Sung JC, Bailey KL, Cody M, McCombs JS (1999) Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 33:281-288